Response to: “Methotrexate Use and Liver Outcomes in Psoriasis and Rheumatoid Arthritis Patients: A Commentary on ‘Risk of liver disease in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis receiving methotrexate: A population-based study'”